NYLIM
RPRX icon

New York Life Investment Management’s Royalty Pharma RPRX Stock Holding History

New York Life Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,966
Closed -$215K – 831
2025
Q2 		$215K Sell
5,966
-602
-9% -$19.9K ﹤0.01% 795
2025
Q1 		$204K Buy
+6,568
New +$208K ﹤0.01% 814
2024
Q2 		– Sell
-6,800
Closed -$207K – 1226
2024
Q1 		$207K Buy
+6,800
New +$200K ﹤0.01% 1317

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's RPRX Position: Q3 2025 in Review

New York Life Investment Management sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 5,966 shares — an estimated $215K sold.

New York Life Investment Management first reported a position in RPRX in Q1 2024 and held it in 3 quarters. The position peaked at $215K in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • New York Life Investment Management reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • New York Life Investment Management sold 5,966 Royalty Pharma shares in Q3 2025, an estimated $215K.
  • New York Life Investment Management first reported a position in Royalty Pharma in Q1 2024 and held it in 3 quarters.
  • New York Life Investment Management's Royalty Pharma position peaked at $215K in Q2 2025.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on New York Life Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.